keyword
MENU ▼
Read by QxMD icon Read
search

Multiple sclerosis drugs

keyword
https://www.readbyqxmd.com/read/28721050/the-use-of-natalizumab-for-multiple-sclerosis
#1
REVIEW
Rachel Brandstadter, Ilana Katz Sand
Natalizumab is a monoclonal antibody that acts as an α4 integrin antagonist to prevent leukocyte trafficking into the central nervous system. It is US Food and Drug Administration (FDA) approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Natalizumab demonstrated high efficacy in Phase III trials by reducing the annualized relapse rate, preventing multiple sclerosis (MS) lesion accumulation on magnetic resonance imaging, and decreasing the probability of sustained progression of disability...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28717429/circulating-concentrations-of-interleukin-il-17-in-patients-with-multiple-sclerosis-evaluation-of-the-effects-of-gender-treatment-disease-patterns-and-il-23-receptor-gene-polymorphisms
#2
Seyed Ali Ghaffari, Maryam Nemati, Hossain Hajghani, Hossainali Ebrahimi, Abdolkarim Sheikhi, Abdollah Jafarzadeh
Background: Interleukin (IL)-17/IL-23 axis performs a prominent role in the pathogenesis of several autoimmune disorders. This study aimed to investigate the concentrations of IL-17 in patients with multiple sclerosis (MS) and its relationship with gender, medication, disease forms and single nucleotide polymorphisms (SNP) in IL-23R gene, including rs11209026 and rs1004819. Methods: The blood specimens were obtained from 135 healthy individuals and 135 MS patients. The patients exhibited relapsing-remitting (RRMS; n = 65), primary progressive (PPMS; n = 19), secondary progressive (SPMS; n = 35) or progressive relapsing (PRMS; n = 14) MS...
January 5, 2017: Iranian Journal of Neurology
https://www.readbyqxmd.com/read/28717427/comparison-of-the-effects-of-low-dose-interferon-and-high-dose-interferon-on-reduction-of-the-number-and-size-of-plaques-in-patients-with-multiple-sclerosis-a-historical-cohort
#3
Payam Khomand, Ghobad Moradi, Behrooz Ahsan, Setareh Abtahi
Background: This study was performed to compare the effects of low dose interferon beta-1 (IFN-β-1) (CinnoVex, 30 mcg) and high dose IFN-β-1 (REBIF, 44 mcg) on the reduction of the number and size of plaques in magnetic resonance imaging (MRI) in patients with multiple sclerosis (MS). Methods: This historical cohort study, which was performed in 2014 in Sanandaj (western part of Iran). 43 MS patients in two groups were investigated. The first group, which included 19 patients, was treated using high dose IFN (44 mcg) and the second group, which was consisted of 24 patients, was treated using low dose IFN (30 mcg)...
January 5, 2017: Iranian Journal of Neurology
https://www.readbyqxmd.com/read/28716230/early-mri-results-and-odds-of-attaining-no-evidence-of-disease-activity-status-in-ms-patients-treated-with-interferon-%C3%AE-1a-in-the-evidence-study
#4
Patricia K Coyle, Anthony T Reder, Mark S Freedman, Juanzhi Fang, Fernando Dangond
INTRODUCTION: 'No evidence of disease activity' (NEDA) is increasingly used as a treatment target with disease-modifying drugs for relapsing multiple sclerosis. METHODS: This post-hoc analysis of the randomised EVIDENCE trial compared interferon beta-1a injected subcutaneously three times weekly (IFN β-1a SC tiw) with interferon β-1a injected intramuscularly once weekly (IFN β-1a IM qw) on NEDA and clinical activity-free (CAF) status. The influence of the frequency of magnetic resonance imaging (MRI) scanning on NEDA and the effect of baseline T1 gadolinium-enhancing (Gd+) lesions on NEDA and CAF were also investigated...
August 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28715462/cell-specificity-dictates-similarities-in-gene-expression-in-multiple-sclerosis-parkinson-s-disease-and-alzheimer-s-disease
#5
Yuichiro Itoh, Rhonda R Voskuhl
Drug repurposing is an efficient approach in new treatment development since it leverages previous work from one disease to another. While multiple sclerosis (MS), Parkinson's disease (PD), and Alzheimer's disease (AD) are all neurodegenerative diseases of the central nervous system (CNS) and differ in many clinical and pathological aspects, it is possible that they may share some mechanistic features. We hypothesized that focusing on gene expression in a CNS cell type specific manner might uncover similarities between diseases that could be missed using whole tissue gene expression analyses...
2017: PloS One
https://www.readbyqxmd.com/read/28713238/targeting-cognitive-impairment-in-multiple-sclerosis-the-road-toward-an-imaging-based-biomarker
#6
Jeroen Van Schependom, Guy Nagels
Multiple Sclerosis (MS) is a neuro-degenerative and -inflammatory disease leading to physical and cognitive impairment, pathological fatigue and depression, and affecting patients' quality of life and employment status. The combination of inflammation, demyelination, and neurodegeneration leads to the emergence of MS lesions, reduced white and gray matter brain volumes, a reduced conduction velocity and microstructural changes in the so-called Normal Appearing White Matter (NAWM). Currently, there are very limited options to treat cognitive impairment and its origin is only poorly understood...
2017: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/28707278/daclizumab-development-clinical-trials-and-practical-aspects-of-use-in-multiple-sclerosis
#7
REVIEW
Laura E Baldassari, John W Rose
Daclizumab is a humanized monoclonal antibody directed towards CD25, the alpha subunit of the high-affinity interleukin (IL)-2 receptor. Daclizumab exerts its effects via multiple mechanisms, including reduction of IL-2-mediated lymphocyte activation and upregulation of CD56-bright natural killer cells. Intravenous daclizumab (Zenapax™) was initially approved for prevention of rejection in renal transplant. In subsequent early testing, followed by larger-scale phase II and phase III trials, both intravenous and subcutaneous daclizumab have demonstrated clinical efficacy in the treatment of multiple sclerosis...
July 13, 2017: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://www.readbyqxmd.com/read/28699780/depression-anxiety-and-stress-severities-in-multiple-sclerosis-patients-using-injectable-versus-oral-treatments
#8
Fawaz Al-Hussain, Noura Al-Salloum, Naael Alazwary, Jameelah Saeedi, Sara Howaidi, Abdulkader Daif
AIM: Studies on multiple sclerosis in Saudi Arabia remain scant, particularly studies on the psychological aspects. This study measures severities of depression, anxiety and stress, and compares them to the used disease-modifying treatment. MATERIALS & METHODS: Cross-sectional study using a phone questionnaire targeting 452 Saudi patients with relapsing-remitting multiple sclerosis following in King Khalid University Hospital, King Fahad Medical City or Security Forces Hospital...
July 12, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28698092/spasticity-in-multiple-sclerosis-contribution-of-inflammation-autoimmune-mediated-neuronal-damage-and-therapeutic-interventions
#9
REVIEW
Robert Patejdl, Uwe K Zettl
In contrast to other diseases that go along with spasticity (e.g. spinal cord injury), spasticity in chronic autoimmune diseases involving the CNS is complicated by the ongoing damage of neuronal networks that leads to permanent changes in the clinical picture of spasticity. Multiple sclerosis (MS) is the most frequent autoimmune disease of the central nervous system (CNS) and spasticity is one of the most disabling symptoms. It occurs in more than 80% MS patients at some point of the disease and is associated with impaired ambulation, pain and the development of contractures...
July 8, 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/28697282/exploring-the-potential-of-natural-and-synthetic-neuroprotective-steroids-against-neurodegenerative-disorders-a-literature-review
#10
REVIEW
Ranju Bansal, Ranjit Singh
Neurodegeneration is a complex process, which leads to progressive brain damage due to loss of neurons. Despite exhaustive research, the cause of neuronal loss in various degenerative disorders is not entirely understood. Neuroprotective steroids constitute an important line of attack, which could play a major role against the common mechanisms associated with various neurodegenerative disorders like Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. Natural endogenous steroids induce the neuroprotection by protecting the nerve cells from neuronal injury through multiple mechanisms, therefore the structural modifications of the endogenous steroids could be helpful in the generation of new therapeutically useful neuroprotective agents...
July 11, 2017: Medicinal Research Reviews
https://www.readbyqxmd.com/read/28695634/patient-reported-outcomes-in-multiple-sclerosis-a-systematic-comparison-of-available-measures
#11
REVIEW
V Khurana, H Sharma, N Afroz, A Callan, J Medin
Multiple patient-reported outcomes (PROs) are currently being used in multiple sclerosis (MS) but their application is inconsistent and guidance on the appropriateness of each tool is lacking. The objective of our study was to identify MS-specific PROs and systematically to assess the development process and the reliability and validity of various instruments. A systematic literature search was conducted on multiple data sources, including MEDLINE, Embase (using the Ovid platform) and Google Scholar, from 1996 to March 2015...
July 11, 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/28695472/assessing-repair-in-multiple-sclerosis-outcomes-for-phase-ii-clinical-trials
#12
REVIEW
Maria Pia Sormani, Matteo Pardini
Multiple Sclerosis (MS) pathology is complex and includes inflammatory processes, neurodegeneration, and demyelination. While multiple drugs have been developed to tackle MS-related inflammation, to date there is scant evidence regarding which therapeutic approach, if any, could be used to reverse demyelination, foster tissue repair, and thus positively impact on chronic disability. Here, we reviewed the current structural and functional markers (magnetic resonance imaging, positron emission tomography, optical coherence tomography, and visual evoked potentials) which could be used in phase II clinical trials of new compounds aimed to foster tissue repair in MS...
July 10, 2017: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://www.readbyqxmd.com/read/28693915/selective-opioid-growth-factor-receptor-antagonists-based-on-a-stilbene-isostere
#13
David P Stockdale, Michelle B Titunick, Jessica M Biegler, Jessie L Reed, Alyssa M Hartung, David F Wiemer, Patricia J McLaughlin, Jeffrey D Neighbors
As part of an ongoing drug development effort aimed at selective opioid receptor ligands based on the pawhuskin natural products we have synthesized a small set of amide isosteres. These amides were centered on lead compounds which are selective antagonists for the delta and kappa opioid receptors. The amide isomers revealed here show dramatically different activity from the parent stilbene compounds. Three of the isomers synthesized showed antagonist activity for the opioid growth factor (OGF)/opioid growth factor receptor (OGFR) axis which is involved in cellular and organ growth control...
June 27, 2017: Bioorganic & Medicinal Chemistry
https://www.readbyqxmd.com/read/28691528/ribbing-disease-a-systematic-review
#14
Bart G Pijls, Koen Steentjes, Jan W Schoones, Sander Pd Dijkstra
Background Ribbing disease, or multiple diaphyseal sclerosis, is a rare benign bone dysplasia. Purpose To systematically review the literature to determine the clinical and radiological presentation of patients with Ribbing disease as well as the effects of attempted treatments. Material and Methods We considered individual patient data of patients diagnosed with Ribbing disease derived from patient reports and patient series. All stages of the review were performed by two reviewers independently. Standard descriptive statistics were used for quantitative analyses and mixed model analyses were used when appropriate Results The literature search yielded 420 unique hits of which 23 studies were included, covering a total of 40 patients of whom 29 had bilateral involvement...
January 1, 2017: Acta Radiologica
https://www.readbyqxmd.com/read/28688015/erratum-to-health-related-quality-of-life-in-patients-with-multiple-sclerosis-impact-of-disease-modifying-drugs
#15
Peter Joseph Jongen
No abstract text is available yet for this article.
July 7, 2017: CNS Drugs
https://www.readbyqxmd.com/read/28687730/fluvoxamine-stimulates-oligodendrogenesis-of-cultured-neural-stem-cells-and-attenuates-inflammation-and-demyelination-in-an-animal-model-of-multiple-sclerosis
#16
Majid Ghareghani, Kazem Zibara, Heibatollah Sadeghi, Shima Dokoohaki, Hossein Sadeghi, Roya Aryanpour, Amir Ghanbari
Multiple Sclerosis (MS) require medications controlling severity of the pathology and depression, affecting more than half of the patients. In this study, the effect of antidepressant drug fluvoxamine, a selective serotonin reuptake inhibitor, was investigated in vitro and in vivo. Nanomolar concentrations of fluvoxamine significantly increased cell viability and proliferation of neural stem cells (NSCs) through increasing mRNA expression of Notch1, Hes1 and Ki-67, and protein levels of NICD. Also, physiological concentrations of fluvoxamine were optimal for NSC differentiation toward oligodendrocytes, astrocytes and neurons...
July 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28687690/cryptococcal-meningitis-causing-obstructive-hydrocephalus-in-a-patient-on-fingolimod
#17
Chengde Pham, Iwan Bennett, Rondhir Jithoo
Cryptococcosis is a recognised opportunistic infection in immunocompromised patients. The long-term adverse effect profile of fingolimod, an immunomodulating agent approved for use in multiple sclerosis in 2010, is only just emerging. We report the first case to our knowledge of a patient presenting with obstructive hydrocephalus secondary to cryptococcal meningitis in the setting of fingolimod therapy. Extensive posterior fossa leptomeningeal inflammation with associated cerebellar oedema resulted in effacement of the fourth ventricle and obstructive hydrocephalus requiring urgent ventriculostomy...
July 6, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28686675/management-of-flu-like-syndrome-with-cetirizine-in-patients-with-relapsing-remitting-multiple-sclerosis-during-therapy-with-interferon-beta-results-of-a-randomized-cross-over-placebo-controlled-pilot-study
#18
Doriana Landi, Maria Albanese, Fabio Buttari, Fabrizia Monteleone, Laura Boffa, Silvia Rossi, Caterina Motta, Elisa Puma, Diego Centonze
BACKGROUND: Flu-like syndrome (FLS) is a common adverse event experienced by patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon beta (IFNβ). FLS can lead to poor treatment adherence and early IFNβ discontinuation. The involvement of interleukin-6 (IL-6) in the occurrence of FLS has been suggested. We hypothesized that cetirizine, a second-generation histamine H1 receptor antagonist able to reduce the levels of IL-6, might improve IFNβ-induced FLS. METHODS: We conducted a pilot, cross-over, randomized, placebo-controlled, double-blind study to evaluate the efficacy of cetirizine 10 mg added after each IFNβ injection to the standard of care for FLS (acetaminophen or nonsteroidal anti-inflammatory drugs) on FLS in patients with RRMS treated with IFNβ...
2017: PloS One
https://www.readbyqxmd.com/read/28686480/caerulomycin-a-suppresses-the-differentiation-of-na%C3%A3-ve-t-cells-and-alleviates-the-symptoms-of-experimental-autoimmune-encephalomyelitis
#19
Weshely Kujur, Rama Krishna Gurram, Sudeep K Maurya, Sajid Nadeem, Sathi Babu Chodisetti, Nargis Khan, Javed Naim Agrewala
Multiple sclerosis (MS) is a highly detrimental autoimmune disease of the central nervous system. There is no cure for it but the treatment typically focuses on subsiding severity and recurrence of the disease. Experimental autoimmune encephalomyelitis (EAE) is an animal model of MS. It is characterized by frequent relapses due to the generation of memory T cells. Caerulomycin A (CaeA) is known to suppress the Th1 cells, Th2 cells, and Th17 cells. Interestingly, it enhances the generation of regulatory T cells (Tregs)...
July 7, 2017: Autoimmunity
https://www.readbyqxmd.com/read/28686222/multiple-sclerosis-immunopathology-and-treatment-update
#20
REVIEW
Narges Dargahi, Maria Katsara, Theodore Tselios, Maria-Eleni Androutsou, Maximilian de Courten, John Matsoukas, Vasso Apostolopoulos
The treatment of multiple sclerosis (MS) has changed over the last 20 years. All immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a medical challenge in MS to develop a treatment for progressive forms. The most common injectable disease-modifying therapies in RRMS include β-interferons 1a or 1b and glatiramer acetate. However, one of the major challenges of injectable disease-modifying therapies has been poor treatment adherence with approximately 50% of patients discontinuing the therapy within the first year...
July 7, 2017: Brain Sciences
keyword
keyword
18958
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"